MIRM ▲ +2.2% - Mirum Pharmaceuticals, Inc. $MIRM Mirum Pharmaceuticals: Phase 3 AZURE-1 Topline Results for Brelovitug Due Sept. 28 ? • Investor call scheduled for 8:30 a.m. ET to present Phase 3 data in chronic hepatitis delta. • Mirum will also report 48-week results from the Phase 2b portion of the study. • Brelovitug is a late-stage monoclonal antibody program for chronic HDV. 27-SEP-2026 06:46 PM ET